Argenx buys Forte Biosciences for $77 per share Argenx SE is acquiring Forte Biosciences for $77 per share in cash, valuing the deal at $2.2B. The acquisition adds Forte's lead program to argenx's portfolio. The deal expands argenx's immunology offerings wi
Argenx buys Forte Biosciences for $77 per share
Argenx SE is acquiring Forte Biosciences for $77 per share in cash, valuing the deal at $2.2B.
The acquisition adds Forte’s lead program to argenx’s portfolio.
The deal expands argenx’s immunology offerings with a first-in-class anti-CD122 antibody.
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
